Prevalence of Germline Mutations Associated with Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms

Autor: Christian Gauthier, Zhengdong Jiang, Ammar A. Javed, Miaozhen Qiu, Alison P. Klein, Jin He, Matthäus Felsenstein, Laura D. Wood, Koji Shindo, Christopher L. Wolfgang, Ralph H. Hruban, Nicholas J. Roberts, Michael Goggins, Michael Skaro, Ross Beckman, Jun Yu, Neha Nanda, Elizabeth D. Thompson, Danielle Hutchings
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Oncology
Adult
Male
medicine.medical_specialty
endocrine system diseases
Pancreatic Intraductal Neoplasms
Ataxia Telangiectasia Mutated Proteins
Article
Neoplasms
Multiple Primary

03 medical and health sciences
0302 clinical medicine
Germline mutation
Risk Factors
Pancreatic cancer
Internal medicine
medicine
Humans
Genetic Predisposition to Disease
Exome
Germ-Line Mutation
Aged
Retrospective Studies
Aged
80 and over

Hepatology
Intraductal papillary mucinous neoplasm
business.industry
Gastroenterology
Cancer
Middle Aged
medicine.disease
Minor allele frequency
Pancreatic Neoplasms
Patched-1 Receptor
Repressor Proteins
030104 developmental biology
medicine.anatomical_structure
Case-Control Studies
Adenocarcinoma
030211 gastroenterology & hepatology
Female
Neoplasm Grading
Pancreas
business
Carcinoma
Pancreatic Ductal
Zdroj: Gastroenterology
Popis: BACKGROUND & AIMS: Many patients with pancreatic adenocarcinoma (PDAC) carry germline mutations associated with increased risk of cancer. It is not clear whether patients with intraductal papillary mucinous neoplasms (IPMNs), which are precursors to some pancreatic cancers, also carry these mutations. We assessed the prevalence of germline mutations associated with cancer risk in patients with histologically confirmed IPMN. METHODS: We obtained non-tumor tissue from 315 patients with surgically resected IPMNs, from 1997 through 2017, and sequenced 94 genes with variants associated with cancer risk. Mutations associated with increased risk of cancer were identified and compared to individuals from the Exome Aggregation Consortium. RESULTS: We identified 23 patients with a germline mutation associated with cancer risk (7.3%; 95% CI, 4.9%–10.8%). Nine patients had a germline mutation associated with pancreatic cancer susceptibility (2.9% 95% CI, 1.4%–5.4%). More patients with IPMNs carried germline mutations in ATM (P
Databáze: OpenAIRE